In summary, we provide compelling in vitro and in vivo evidence demonstrating that METTL3 could enhance TGFB2 mRNA translation and trigger TGF-β signaling cascades, thereby modulating cEndMT process and FECD progression. This evidence concerns the gene METTL3 and Fuchs endothelial corneal dystrophy.